Eli Lilly Secures Legal Protection for Key Obesity Drugs Amid Strong Demand

Eli Lilly secures legal win against copycats as prescription data for Zepbound and Mounjaro remains robust. Analysts see stock dip as a buying opportunity ahead of key FDA decision.

Pharmaceutical giant Eli Lilly has successfully utilized the legal system to defend its profitable position in the weight-loss medication market. A recent court ruling empowers the company to take action against misleading marketing practices by unauthorized copycat products. This development comes as the underlying demand for Lilly's original treatments remains exceptionally strong, despite a notable correction in the company's share price in recent weeks.

Robust Prescription Data Offsets Market Volatility

While Eli Lilly's stock has faced pressure, the fundamental business case for its flagship products appears solid. Current market data reveals sustained, high demand. According to analysts at Morgan Stanley, the anti-obesity drug Zepbound recorded 608,600 prescriptions in the week ending March 20, with more than half attributed to new patients. During the same period, the diabetes treatment Mounjaro, which shares the active ingredient tirzepatide, saw 729,600 prescriptions.

Market experts interpret these volumes as a positive signal, suggesting a potential upside of six percent to existing revenue estimates for these two primary growth drivers through 2026.

Court Grants Preliminary Victory in Consumer Protection Case

On the legal front, Eli Lilly achieved a significant interim victory last Friday in its case against Fella Health. The presiding court allowed key claims to proceed, alleging consumer deception and false advertising related to compounded versions of the blockbuster drug tirzepatide. This legal maneuver is designed to safeguard the intellectual property of the high-revenue GLP-1 class medications and protect the integrity of the company's portfolio.

Market observers largely view the stock's recent performance as a technical adjustment following substantial gains in previous years. Shares closed Friday's session down 2.30 percent at €761.70, bringing the year-to-date decline to approximately 17 percent.

Analyst Confidence and Strategic Diversification

Institutional investors appear to be viewing the lower valuations as a buying opportunity. For instance, Meadowbrook Wealth Management recently increased its holdings significantly. The analyst community also maintains a predominantly positive outlook. Morgan Stanley reaffirmed its "Overweight" rating, while Erste Group Bank raised its 2027 earnings per share forecast to $42.60.

Beyond its dominant metabolic disease portfolio, Eli Lilly continues to diversify its revenue streams. New long-term data for the atopic dermatitis treatment Ebglyss shows that 80 percent of patients maintained clear skin over four years with monthly dosing.

Upcoming FDA Decision Marks Key Catalyst

Investors are now looking ahead to a major regulatory milestone. The market anticipates a decision from the U.S. Food and Drug Administration (FDA) on orforglipron by April 10, 2026. A potential approval for this experimental oral weight-loss pill is considered a crucial strategic component. It would help the company compete more effectively in the growing market against injectable therapies and potentially reach new patient demographics.